Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator’s Global Assessment: A Post Hoc Analysis of a Phase 3 Trial

In young children, atopic dermatitis (AD) imposes a multidimensional burden on many aspects of their quality of life (QoL) and that of their families. LIBERTY AD PRESCHOOL part B was a randomized, double- blinded, placebo-controlled phase 3 trial in 162 children (aged 6 months to 5 years) with moder...

Full description

Bibliographic Details
Main Authors: Michael J. Cork, Benjamin Lockshin, Andreas Pinter, Zhen Chen, Brad Shumel, Randy Prescilla
Format: Article
Language:English
Published: Medical Journals Sweden 2024-02-01
Series:Acta Dermato-Venereologica
Subjects:
Online Access:https://medicaljournalssweden.se/actadv/article/view/13467